From starting mechanical ventilation to ventilator-associated pneumonia, choosing the right moment to start antibiotic treatment by unknown
RESEARCH Open Access
From starting mechanical ventilation to
ventilator-associated pneumonia, choosing
the right moment to start antibiotic
treatment
Paula Ramirez1,2*, Cristina Lopez-Ferraz1, Monica Gordon1, Alexandra Gimeno3, Esther Villarreal1, Jesús Ruiz1,
Rosario Menendez2,3 and Antoni Torres2,4
Abstract
Background: Ventilator-associated pneumonia (VAP) can have a clear onset or may be a result of the gradual
appearance of symptoms and signs of VAP (gradual VAP). The aim of this paper is to describe the VAP development
process with the intention of discriminating between those pneumonias with a clear beginning and those that are
diagnosed after a period of maturation. In addition, we evaluate the effect of the starting time of antibiotic treatment
in both situations.
Methods: Consecutive ventilated patients fulfilling VAP criteria were included. The patients were monitored for
clinical, microbiological, and inflammatory signs. Patients with VAP were classified into two groups: (1) nongradual
VAP (patients in whom all VAP criteria were detected for the first time on the day of diagnosis) and (2) gradual
VAP (progressive appearance of signs and symptoms throughout the pre-VAP period [<96 h to >24 h before
VAP diagnosis]).
Results: A total of 71 patients with VAP were identified, of whom 43 (61 %) had gradual VAP, most of whom
(n = 38, 88 %) had late-onset VAP. Antibiotic treatment was given to 34 (79 %) patients with gradual VAP in the
pre-VAP period, and empirical antibiotic treatment was appropriate in 22 patients (51 %). The patients with an
appropriate empirical treatment had a higher percentage of early clinical response to treatment (68 % [n = 15] vs.
28 % [n = 7]; p = 0.009). An attempt was made to find a diagnostic test capable of identifying the infectious
process underway, but clinical scales and biomarkers of inflammation helped us to achieve acceptable results.
Conclusions: Gradual emergence of VAP, mainly of late onset, is a common condition. Clinicians should be aware
of this gradual onset of the infection to establish an early antibiotic treatment, even before the classic diagnostic
criteria for VAP are applied.
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Background
The diagnosis of ventilator-associated pneumonia (VAP)
requires compliance with clinical, microbiological, and
radiological criteria [1–3]. However, any clinician would
be able to report those cases in which, although there
are suggestive elements of lung infection, the criteria for
a standard VAP diagnosis are not met. In these cases,
doctors face the question whether to start an antibiotic
treatment. This situation has probably led to the emer-
gence of new diagnostic standards. One of these new
approaches has been named ventilator-associated tra-
cheobronchitis (VAT) [4–9]. In fact, lower mortality has
been prospectively demonstrated in those patients with
VAT appropriately treated with antibiotics [9]. However
VAT differs from VAP only by the absence of pulmonary
infiltrates on chest x-rays, and pulmonary consolidation
can frequently be misdiagnosed on the basis of chest
x-rays of mechanically ventilated patients [2, 10].
According to clinical practice, it appears that the pro-
gressive development of VAP requires a more complex
approach than the radiological differentiation between
VAT and VAP. From the start of mechanical ventilation,
artificial airway and bacterial colonization pose a challenge
to the patient´s host defense system. As a result of this
challenge, patients can present with fever, an elevated
white cell count, or an increase in the amount of respira-
tory secretions (and even the development of purulence).
A respiratory culture will reveal the presence of microor-
ganisms. Throughout this confrontation, clinicians should
recognize the right moment to start antibiotic treatment.
We hypothesized the existence of two different path-
ways to VAP: VAP with a clear onset and VAP arising
after a prodromal development period. In this paper, we
aim to describe both pathways analyze the effect of start-
ing antibiotic treatment in the early stages.
Methods
Study design and inclusion criteria
We performed a prospective observational study in a
24-bed medical intensive care unit (ICU) of a 1200-bed
university hospital over an 18-month period. All patients
under mechanical ventilation (for at least 48 h) were
followed for the development of VAP. Nonquantitative
tracheobronchial aspirates (TBAS) and serum inflamma-
tory biomarkers were analyzed every 48–72 h. Patients
with VAP were included in the study and were classified
into two groups: (1) gradual VAP and (2) nongradual
VAP. The Hospital la Fe Institutional Review Board ap-
proved the study, and informed consent was obtained
from the patients’ relatives.
Data collection protocol
The following data were collected upon enrollment into
the study: sex, comorbidities, and severity scores before
intubation (including Acute Physiology and Chronic
Health Evaluation II score) [11], Sepsis-related Organ
Failure Assessment score [12], and modified Clinical
Pulmonary Infection Score [mCPIS] [13]), together with
the reason for ICU admission and for starting mechan-
ical ventilation. Pulmonary infection was monitored by
means of daily evaluation of signs and symptoms and by
calculating the mCPIS. The presence of nonpulmonary
infections was established according to Centers for
Disease Control and Prevention criteria [14].
Definitions
VAP
VAP was defined as two or more of the following:
temperature above 38 °C, white cell count above
12,000/mm3 or below 4000/mm3, or purulent respira-
tory secretions, plus a new or progressive pulmonary
infiltrate on the chest x-ray. VAP confirmation was
defined by the quantitative culture of TBAS greater
than or equal to 105 cfu/ml2, bronchoalveolar lavage
(BAL) with at least 104 cfu/ml, or mini-BAL with at
least 103 cfu/ml [1–3, 15].
Gradual VAP
Gradual VAP was defined as presence in the pre-VAP
period of purulent respiratory secretions, plus one or
both of the following: temperature above 38 °C and a
white cell count greater than 12,000/mm3, and without a
new or progressive pulmonary infiltrate on a chest x-ray.
Nongradual VAP
Nongradual VAP was defined as VAP not fulfilling grad-
ual VAP criteria.
Pre-VAP period
The pre-VAP period was defined as less than 96 h and
more than 24 h before VAP diagnosis. The pre-VAP
period is shown in Fig. 1.
Assessment of VAP clinical response at 72 h
Nonresponders were considered as those patients in
whom at least one of the following criteria was present:
(1) absence of improvement in the ratio of partial
pressure of arterial oxygen to fraction of inspired oxy-
gen; (2) persistence of fever (≥38 °C), or hypothermia
(<35 °C), together with purulent respiratory secre-
tions; (3) greater than 50 % increase in respiratory in-
filtrate on a chest x-ray; and (4) the development of
septic shock or multiorgan failure [16].
Study of inflammatory markers
Blood samples were centrifuged (1500 rpm for 10 minutes),
and the separated serum was frozen at −80 °C. Procalcito-
nin (PCT) was measured using time-resolved amplification
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of cryptate emission technology in a KRYPTOR analyzer
(B∙R∙A∙H∙M∙S, Berlin, Germany). C-reactive protein (CRP)
was measured using an immunoturbidimetric method with
a commercially available kit (Tina-quant C-Reactive Pro-
tein; Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Continuous variables were compared using Student’s t test
for normally distributed variables and the Mann-Whitney
U test for nonnormally distributed variables. Categorical
variables were compared using the χ2 and Fisher’s exact
tests, where appropriate. The threshold for statistical sig-
nificance of the tests was set at 5 %. Collected data were
entered and analyzed using SPSS 15.0 software (SPSS,
Chicago, IL, USA).
Results
Description of the population
Four hundred forty patients receiving mechanical ven-
tilation were screened during the study period, and
71 (16 %) patients with VAP were identified. Of these
71 patients, 43 (61 %) had gradual VAP and 28 (39 %) had
nongradual VAP (Fig. 2). The reasons for ICU admission
and patient comorbidities are summarized in Table 1.
Patient characteristics at ICU admission were similar
between the two groups.
Pre-VAP period characteristics
Table 2 shows the characteristics of the patients in
the pre-VAP period. Patients with gradual VAP had a
higher CPIS in the pre-VAP period (5 [5–7] vs. 4 [1.5–5];
p = 0.018). Although not statistically significant, serum
CRP was clearly higher in patients with gradual VAP. Air-
way colonization was more frequent in patients with grad-
ual VAP; the microorganisms involved were Acinetobacter
baumannii (33 %), Pseudomonas aeruginosa (18 %), and
methicillin-sensitive Staphylococcus aureus (9 %). Most
(79 %) of the patients with gradual VAP received antibiotic
treatment in the pre-VAP period due to the presence of
lung infection symptoms. The antibiotic treatment was
appropriate in 51 % of cases (n = 22). None of the patients
with nongradual VAP were treated in the pre-VAP period.
VAP characteristics
Table 3 shows the characteristics of patients at the time
of VAP diagnosis (gradual vs. nongradual VAP). No dif-
ferences could be found with regard to etiology, inflam-
matory response, severity scores, or outcomes depending
on the presence (or not) of a developing period. Late-
onset VAP was more common in the gradual VAP group
(38 [88 %] vs. 12 [42 %]; p < 0.001). The VAP origin was
Fig. 1 Time frames in the gradual and nongradual ventilator-associated pneumonia (VAP) groups. Colour represents an abrupt VAP onset in the
first line and a gradual VAP onset in the second
Fig. 2 Inclusion algorithm. VAP ventilator-associated pneumonia
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due to the microorganisms isolated at the time of the
developing period in 100 % of cases.
Appropriate antibiotic treatment introduced in the
pre-VAP period in the gradual VAP group was associ-
ated with a higher rate of early clinical response (68 %
[n = 15] vs. 28 % [n = 7]; p = 0.009). However, ICU
mortality and 28-day mortality were not influenced by
the use of appropriate treatment in the pre-VAP period.
Biomarker kinetics
CRP and PCT kinetics from the pre-VAP period to the
diagnosis of the infection were analyzed and compared
Table 1 Patient characteristics at intensive care unit admission
All patients (n = 71) Nongradual VAP (n = 28) Gradual VAP (n = 43) p Value
Age, years 61 [53–71.5] 60 [54.5–73] 63 [50–71] 0.874
Male sex 45 (63 %) 15 (53 %) 30 (70 %) 0.166
Smoking 29 (41 %) 9 (32 %) 20 (46 %) 0.229
Alcohol 14 (20 %) 9 (32 %) 5 (12 %) 0.034
APACHE II score 23 [18.5–28.5] 21.5 [18.5–25.5] 25 [18.5–31.5] 0.166
Comorbidities
Hypertension 32 (45 %) 12 (43 %) 20 (46 %) 0.762
Diabetes mellitus 17 (24 %) 8 (28 %) 9 (21 %) 0.461
Chronic cardiac failure 3 (4 %) 0 3 (7 %) 0.171
Chronic renal failure 8 (11 %) 2 (7 %) 6 (14 %) 0.466
Chronic lung disease/COPD 11 (15 %) 3 (11 %) 8 (19 %) 0.469
Immunosuppression 22 (31 %) 8 (29 %) 14 (32 %) 0.723
Reason for intubation
Respiratory failure 29 (41 %) 11 (39 %) 18 (42 %) 0.754
Cardiovascular failure 12 (17 %) 5 (18 %) 7 (16 %) 0.488
Coma 30 (42 %) 12 (43 %) 18 (42 %) 0.813
SOFA 11 [7.5–12.5] 11 [7–13] 11 [8–12] 0.928
CPIS 4 [3.5–5] 4 [3.5–5] 4 [3–5] 0.431
PaO2/FiO2 195 [100–250] 175 [120.5–250] 200 [69.5–250] 0.816
Temperature, °C 36.3 [36–36.9] 36.2 [36–36.9] 36.5 [36–36.9] 0.815
Leukocytes, cells/mm3 11,100 [9150–14,900] 11,100 [10600–12,300] 11,750 [8500–20,800] 0.729
CRP, mg/L 28 [0.5–104] 111 [6–250] 19 [0.5–70.2] 0.165
PCT, ng/ml 0.26 [0.01–1.44] 0.39 [0.01–1.44] 0.17 [0.01–0.76] 0.743
APACHE II Acute Physiology and Chronic Health Evaluation II, COPD chronic obstructive pulmonary disease, SOFA sepsis organ failure score, CPIS Clinical Pulmonary
Infection Score, CRP C-reactive protein, PCT procalcitonin, PaO2/FiO2 ratio of partial pressure of arterial oxygen to fraction of inspired oxygen
Results are expressed as median [interquartile range] for continuous variables and number (%) for categorical variables
Table 2 Patient characteristics in pre-VAP period
All patients (n 71) Nongradual VAP (n 28) Gradual VAP (n 43) p Value
Airway bacterial colonization 62 (87 %) 19 (68 %) 43 (100 %) <0.001
SOFA 7.5 [5–10.5] 8 [0–10] 7 [5.5–10.5] 0.922
mCPIS 5 [4–6] 4 [1.5–5] 5 [5–7] 0.018
PaO2/FiO2 200 [148–274] 200 [140.5–267] 200 [164–280] 0.596
Temperature, °C 37 [36.2–38] 36.4 [36–37.9] 37.2 [36.6–38] 0.05
Leukocytes, cells/mm3 12,400 [7900–16,800] 11,550 [8200–17,500] 12,700 [7200–16,550] 0.984
CRP, mg/L 134 [52–208] 76 [13.5–164] 159 [80–210] 0.051
PCT, ng/ml 0.83 [0.37–3.96] 0.78 [0.27–7.6] 0.9 [0.43–2.16] 0.953
SOFA sepsis organ failure score, mCPIS modified Clinical Pulmonary Infection Score, CRP C-reactive protein, PCT procalcitonin, PaO2/FiO2 ratio of partial pressure of
arterial oxygen to fraction of inspired oxygen, VAP ventilator-associated pneumonia
Results are expressed as median [interquartile range] for continuous variables and number (%) for categorical variables
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between the two groups (Table 4). In both groups, bio-
markers showed an increasing pattern (statistically sig-
nificant for PCT), except for CRP in gradual VAP.
Antibiotic treatment guide
Recognized cutoffs for antibiotic guidance in serum PCT
(≥0.5 ng/ml and >1 ng/ml) and modified mCPIS (>5
points) were assessed to establish their capacity to
identify an ongoing infection. Better rates were achieved
with mCPIS (sensitivity 44 %, specificity 92 %, positive
predictive value 92 %, negative predictive value 48 %,
(Likelihood ratio) LH+ 6.67, LH− 0.60, AUC 0.670,
95 % CI 0.545–0.796; p = 0.016). The AUCs for CRP
and PCT were 0.678 and 0.505, respectively. CRP and
PCT were ineffective in identifying gradual VAP
(Table 5).
Discussion
To our knowledge, we are the first to describe the con-
cept of gradual VAP. Establishment of gradual VAP is a
common process, mainly in the case of late pneumonia.
More importantly, our data support the need to initiate
proper antibiotic treatment in the early stages of infec-
tion without waiting for all the diagnostic criteria for
VAP to be met. However, in this study, we were unable
Table 3 Patient characteristics at time of ventilator-associated pneumonia diagnosis
All patients (n = 71) Nongradual VAP (n = 28) Gradual VAP (n = 43) p Value
MV duration before VAP, days 7 [4.5–10.5] 4.5 [3–9] 8 [6.5–11.5] 0.002
Early VAP 21 (29 %) 16 (57 %) 5 (12 %) <0.001
SOFA score 5.5 [8–11.5] 10 [8–12] 7 [5–11] 0.142
mCPIS score 7 [6–8] 7 [6–8] 7 [6–8] 0.908
PaO2/FiO2 197 [137–247] 200 [160–282] 180 [130–226] 0.119
Temperature, °C 38 [37–38.7] 38 [36.7–38.6] 38 [37–38.7] 0.928
Leukocytes, cells/mm3 12250 [8050–17,400] 12,000 [9100–16,800] 12,400 [7500–17,500] 0.930
CRP (mg/L) 151 [90–315] 200 [100–340] 132 [73.5–265] 0.301
PCT (ng/ml) 1.4 [0.5–4.3] 1.4 [0.5–6.08] 1.4 [0.5–4.1] 0.961
Etiology
Nonfermenting GNB 42 (52 %) 17 (61 %) 25 (58 %) 0.829
Enterobacteriaceae 14 (20 %) 6 (21 %) 8 (19 %) 0.770
Staphylococcus aureus 8 (11 %) 2 (7 %) 6 (14 %) 0.315
Haemophilus influenzae 5 (7 %) 2 (7 %) 3 (7 %) 0.661
Streptococcus 1 (1 %) 0 1 (2 %) 0.606
Aspergillus 1 (1 %) 1 (3 %) 0 0.394
Treatment failure (72 h) 39 (55 %) 17 (61 %) 22 (51 %) 0.442
Microbial persistence (72 h) 43 (61 %) 16 (57 %) 27 (63 %) 0.361
Relapse 8 (11 %) 3 (11 %) 5 (11 %) 0.121
ICU stay, days,) 19 [13–29] 16 [12–28.5] 20.5 [14–29] 0.346
Hospital stay, days 24 [12–51] 19.5 [9–42] 29 [16–57] 0.054
Days of MV 13 [8–18] 13.5 [8.5–19.5] 12.5 [8–17] 0.679
28-day mortality 43 (61 %) 18 (64 %) 25 (58 %) 0.605
MV mechanical ventilation, VAP ventilator-associated pneumonia, SOFA Sepsis-related Organ Failure Assessment, mCPIS modified Clinical Pulmonary Infection
Score, CRP C-reactive protein, PCT procalcitonin, GNB gram-negative bacteria, PaO2/FiO2 ratio of partial pressure of arterial oxygen to fraction of inspired oxygen,
ICU intensive care unit
Results are expressed as median [interquartile range] for continuous variables and number (%) for categorical variables
Table 4 Biomarker kinetics
Pre-VAP CRP (mg/dl) VAP CRP (mg/ml) p Value Pre-VAP PCT (ng/dl) VAP PCT (ng/ml) p Value
Nongradual VAP 76 [9.75–186] 200 [99–347] 0.565 0.78 [0.25–9.09] 1.41 [0.5–6.2] 0.006
Gradual VAP 159 [80–210] 132 [67.7–268.5] 0.502 0.9 [0.42–2.35] 1.42 [0.56–4.21] 0.008
CRP C-reactive protein, PCT procalcitonin, VAP ventilator-associated pneumonia
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to identify effective diagnostic tools for gradual VAP,
apart from the usual clinical criteria.
In line with the idea proposed by Craven and Hjalmarson
[4], our study supports the hypothesis of a continuum be-
tween airway colonization, an intermediate process (called
ventilator-associated tracheobronchitis in their study), and
VAP. During this developing period, the patient’s immune
system will attempt to prevent the spread of the organism,
and signs of this confrontation will be observable in the
form of fever, leukocytosis, and purulent bronchial secre-
tions. This process is typical in late-onset VAP (76 % of late
VAP cases in our series were gradual VAP), and its absence
is probably justified by the presence of a sudden and large
bacterial inoculum into the lung (inoculate at intubation in
early VAP, and due to accidental aspiration of subglottic se-
cretions in late VAP).
Our results do not support a nosological separation
between VAP and VAT. As described in the literature,
VAP and VAT are distinguishable only by the presence
of visible lung infiltrate on a chest x-ray. However, the
discriminative ability of a portable chest x-ray is more
than doubtful. In fact, even in community-acquired
pneumonia, plain radiography has shown a diagnostic
inaccuracy of 17 % compared with chest computed tom-
ography [10]. Nonetheless, the value of studying VAP
development lies in antibiotic prescription rather than in
a diagnostic disquisition.
In our study, appropriate antibiotic treatment intro-
duced in the developing period in gradual VAP was as-
sociated with a higher rate of early clinical response.
Therefore, identifying the right moment to start antibi-
otics in this continuum between colonization and VAP
seems to be a challenge. PCT may be a valuable tool in
this context. Stolz et al. showed a safety algorithm for
antibiotic discontinuation based on serum PCT after
72 h of antibiotic treatment in 101 patients with VAP
[17]. In our study, gradual VAP showed serum PCT
greater than or equal to 0.5 ng/ml during the developing
period in 65 % of cases, but this was also true for non-
gradual VAP in 60 % of cases.
According to our results, in the event of suspected
VAP, a mCPIS score higher than 5 could indicate anti-
biotic initiation. However, the lack of sensitivity of
mCPIS in our study precludes a safe use of this tool to
rule out the existence of an ongoing infectious process.
Using a different methodological approach, Singh et al.
demonstrated the usefulness of CPIS to safely withdraw
antibiotics after 72 h of treatment in patients with an
initial but incomplete diagnosis of VAP (CPIS ≤6 points
at inclusion) [18].
Our study has several limitations. The sample size is
not large and could be responsible for the observed
negative results. However, our sample size is not too far
removed from that used in studies by Stolz et al. [17]
and Singh et al. [18]. Gradual VAP definition is roughly
equal to VAT criteria, but in our case it systematically
preceded the diagnosis of VAP. In any case, we avoid
discussion of labeling of patients, as our objective is to
analyze the correct time for starting antibiotic treatment.
In this sense, the progression to VAP is marked, despite
an appropriate antibiotic treatment. Although this
phenomenon has already been described [9], we would
need to analyze the characteristics of patients in similar
clinical conditions, but without progression to VAP, to
get convincing explanations. We believe that nongra-
dual late VAP may be due to accidental inoculation of
heavily colonized oropharynx secretions. However, we
had little knowledge regarding the existence of this type
of incident in such cases. Finally, we must assume that
demonstration of the clinical importance of the concept
of gradual VAP requires additional studies based on
therapeutic interventions. Since this type of interven-
tion may lead to a greater consumption of antibiotics, it
should always be associated with an antimicrobial stew-
ardship program.
Conclusions
Not all pneumonias are developed similarly, which is
probably due to differences in the pathogenic mechanism.
But what is really important is the identification of the in-
fectious process in place, in order to start appropriate
antimicrobial therapy. According to our results, antibiotic
treatment should not be delayed, even if the patient does
not meet the prescriptive diagnostic criteria for VAP.
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Table 5 Identification of gradual ventilator-associated pneumonia with assessment of diagnostic tool parameters
AUC 95 % CI p Value Sensitivity Specificity Likelihood ratio
Positive Negative
PCT ≥0.5 ng/ml 0.505 0.332–0.677 0.953 65 40 1.08 0.88
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